Ganymed

Results: 81



#Item
11

Press Release GANYMED ernennt Dr. Rainer Wessel zum Vorstandsvorsitzenden Mainz, Deutschland, 1. April 2004 GANYMED Pharmaceuticals AG ist ein unabhängiges Biotechnologieunternehmen mit Schwerpunkt Krebserkrankungen. GA

Add to Reading List

Source URL: www.ganymed-pharmaceuticals.com

- Date: 2015-02-04 05:14:58
    12

    Press Release GANYMED names Rainer Wessel Ph.D. as President & CEO Mainz, Germany / April 1, 2004 GANYMED Pharmaceuticals AG, an independent biotechnology company with an initial focus on cancer, announced that Rainer We

    Add to Reading List

    Source URL: www.ganymed-pharmaceuticals.com

    - Date: 2015-02-04 05:14:57
      13

      Press Release GANYMED Pharmaceuticals AG sichert sich in der ersten Finanzierungsrunde 8,85 Millionen Euro Mainz, im Juni 2002 GANYMED Pharmaceuticals AG hat seine erste Finanzierungsrunde abgeschlossen. Zusammen mit dem

      Add to Reading List

      Source URL: www.ganymed-pharmaceuticals.com

      - Date: 2015-02-04 05:15:01
        14

        Ganymed Pharmaceuticals AG ist ein unabhängiges forschendes Biotechnologieunternehmen in Mainz, das hochwirksame Immuntherapeutika gegen neuartige Zielstrukturen zur Behandlung von Krebserkrankungen entwickelt. Unsere M

        Add to Reading List

        Source URL: www.ganymed-pharmaceuticals.com

        - Date: 2016-05-17 04:46:51
          15

          Microsoft WordGanymed Corporate Overview.docx

          Add to Reading List

          Source URL: www.ganymed-pharmaceuticals.com

          - Date: 2016-06-03 05:53:34
            16

            Press Release Ganymed acquires ImmuGenics AG and In-licenses Technology from Imperial College London Mainz, December 1, 2003 Ganymed Pharmaceuticals AG, an independent biotechnology company that identifies and validates

            Add to Reading List

            Source URL: www.ganymed-pharmaceuticals.com

            - Date: 2015-02-04 05:14:59
              17

              PRESS RELEASE – PRESSEINFORMATION GANYMED raises EUR 14.4 million in Series B Financing Round Mainz, Germany (July 06, 2005) – GANYMED Pharmaceuticals AG, a privately held antibody development company with a focus o

              Add to Reading List

              Source URL: www.ganymed-pharmaceuticals.com

              - Date: 2015-02-04 05:15:01
                18

                Ganymed Pharmaceuticals AG is a young and successful biopharmaceutical company located in Mainz, developing innovative antibody therapies against cancer. At the earliest possible point in time, the following vacancy is t

                Add to Reading List

                Source URL: www.ganymed-pharmaceuticals.com

                - Date: 2016-07-06 08:10:25
                  19

                  Microsoft Word - GANYMED_Press_Release_German_2007_09_18_Final.doc

                  Add to Reading List

                  Source URL: www.ganymed-pharmaceuticals.com

                  - Date: 2015-02-04 05:14:58
                    20

                    Press Release GANYMED names 3 pharmaceutical industry executives to its Supervisory Board Mainz, November 12, 2003 GANYMED Pharmaceuticals AG, an independent biotechnology company that identifies and validates antigen ta

                    Add to Reading List

                    Source URL: www.ganymed-pharmaceuticals.com

                    - Date: 2015-02-04 05:15:08
                      UPDATE